Speculating in Takeover Targets Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Speculating in Takeover Targets

ULBI 5.880

-4.9%

Jan 9 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: richardred who wrote (2625)	7/16/2012 12:08:53 PM
From: richardred	Read Replies (1) of 7256

Thermo Fisher Acquiring Transplant-Testing Company By MICHAEL KREY, INVESTOR'S BUSINESS DAILY Posted 11:44 AM Thermo Fisher Scientific (TMO), a maker of instruments and tests used to analyze lab samples, early Monday said it would buy privately held transplant-testing company One Lambda for $925 million. The purchase will help Thermo Fisher expand in the specialty diagnostics market. "One Lambda is an exciting addition to our specialty diagnostics portfolio," Thermo Fisher CEO Marc Casper said in the company's press release. The 320-employee One Lambda makes products used by transplant centers to test tissues mainly to determine the compatibility of potential transplant donors and recipients. Its tests are designed to detect the presence of antibodies that can lead to transplant rejection. Thermo Fisher said the deal will add 9 cents to 11 cents in earnings per share minus items in 2013. Shares of Waltham, Mass.-based Thermo Fisher were up a fraction in early trading Monday, near 52.10. The stock has fallen 18% in the past year. "We view this deal positively from both a strategic and financial perspective," ISI Group analyst Ross Muken wrote in a report. He says it strengthens Thermo Fisher in the specialty diagnostics field. He called the price "reasonable" and boosted his fiscal 2013 per-share profit estimate to $5.56 from $5.47. He also raised his stock price target to 61 from 60. Reuters noted that the deal is Thermo Fisher's third and biggest acquisitions this year and follows a string of other deals in the diagnostics sector. Agilent Technologies (A) in May announced it would buy Danish cancer diagnostics company Dako for $2.2 billion. In April, Hologic (HOLX) said in April it would buy Gen-Probe for $3.75 billion. Thermo Fisher bought Sweden-based diagnostics firm Phadia last year for $3.5 billion. news.investors.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next